Disclaimer: This article is for general educational purposes only and does not provide medical or dosing advice. Always encourage customers to consult a pharmacist or healthcare professional for guidance on individual use. In case of overdose or poisoning, contact the US Poison Help Line at 1‑800‑222‑1222 immediately (US).

What Is the OTC Monograph System?

The OTC monograph system is a regulatory “rule book” established under section 505 of the Federal Food, Drug, and Cosmetic (FD&C) Act. It defines what active ingredients, doses, routes of administration, formulations, labeling, and testing criteria are generally recognized as safe and effective (GRASE) for specific therapeutic categories such as antacids, sunscreens, or cough suppressants. Products that conform to an existing monograph may be marketed over the counter without requiring individual FDA pre‑market approval. FDA: OTC monographs describe conditions under which OTC drugs are GRASE ([fda.gov](https://www.fda.gov/drugs/how-drugs-are-developed-and-approved/over-counter-otc-nonprescription-drugs?utm_source=openai))

How Was the System Modernized? CARES Act & Section 505G

In March 2020, the CARES Act added section 505G to the FD&C Act, modernizing the OTC monograph system. Instead of slow rulemaking, FDA now uses a streamlined administrative order process to add, remove, or change monograph conditions. These administrative orders—proposed and final—undergo public comment and may be initiated by either FDA or industry via an OTC Monograph Order Request (OMOR). FDA: CARES Act added section 505G and enabled administrative orders ([fda.gov](https://www.fda.gov/drugs/otc-drug-review-process-otc-drug-monographs?utm_source=openai))

Administrative Orders & Industry Participation

Under the revised system, both FDA and industry stakeholders may propose changes through OMORs. Once FDA accepts an OMOR for filing, a proposed administrative order is published and subject to at least 45 days of public comment. After review, a final administrative order may be issued with options for dispute resolution and judicial review. In urgent situations—such as serious safety risks—FDA may expedite the process. Details on administrative order and public comment process ([fda.gov](https://www.fda.gov/drugs/otc-drug-review-process-otc-drug-monographs?utm_source=openai))

User Fees & OMUFA II Funding

To support the modernized monograph system, the CARES Act also authorized the Over‑the‑Counter Monograph Drug User Fee Program (OMUFA). Under OMUFA and its 2025 reauthorization (OMUFA II), FDA collects facility fees and OMOR submission fees to fund timely review and administrative operations. OMUFA II covers fiscal years 2026–2030 and ensures predictable funding and performance goals. FDA: OMUFA II reauthorization provides funding stability ([fda.gov](https://www.fda.gov/industry/fda-user-fee-programs/omufa-reauthorization-fiscal-years-2026-2030?utm_source=openai))

For example, the FY 2027 facility and OMOR fee rates were published by FDA effective October 1, 2026. OMUFA II consolidates fee notices into a single annual notice and includes clear deadlines for payment installments. FDA: FY 2027 OMUFA fee rates and schedule ([fda.gov](https://www.fda.gov/industry/fda-user-fee-programs/over-counter-monograph-drug-user-fee-program-omufa?utm_source=openai))

Key Components Defined by Monograph Conditions

  • Active ingredients and doses – Exact substances and dose levels (e.g., mg per tablet or % in topical creams) are specified.
  • Purposes and indications – Clear intended uses (e.g., anti‑acid relief, sunscreen protection).
  • Labeling requirements – Standardized Drug Facts panels with required elements: active ingredients, uses, warnings, directions, inactive ingredients, and other information.
  • Testing and quality – Products must meet standards for identity, strength, purity, and quality, often aligned with USP–NF or other recognized standards.

Why the OTC Monograph System Matters

This system allows for timely consumer access to safe, effective OTC products that meet established GRASE standards—without the complexity of new drug applications. The streamlined administrative order process under 505G enables FDA to update monographs efficiently in response to emerging data. OMUFA funding helps ensure reviews occur within performance timelines. FDA: OMUFA ensures efficient regulatory performance ([fda.gov](https://www.fda.gov/drugs/our-perspective/our-perspective-omufa-past-current-and-future?utm_source=openai))

Best Practices for DocAiPharmacy

  • Ensure OTC products align with current monograph conditions and relevant administrative orders.
  • Train staff to recognize monograph-defined active ingredients, doses, and required labeling elements.
  • Encourage customers to review Drug Facts panels carefully and seek pharmacist guidance when unclear or if symptoms persist.

Pharmacist Consultation Guidance: This article is not a substitute for professional advice. Pharmacists should ensure proper product selection and labeling compliance, counsel consumers on safe use, and direct them to medical attention if needed. In case of overdose in the US, call 1‑800‑222‑1222.

Educational Disclaimer & Recap

This article is intended solely for educational purposes at DocAiPharmacy. It does not provide individualized medical, dosing, or treatment recommendations. Always consult a pharmacist or qualified healthcare provider for personal health advice.

Official sources

Product added to compare.

iqitcookielaw - module, put here your own cookie law text

Product added to wishlist